Connect with us

The Worldwide Biotechnology & Pharmaceutical Services Outsourcing Industry is Expected to Reach $108 Billion by 2030

The Worldwide Biotechnology & Pharmaceutical Services Outsourcing Industry is Expected to Reach $108 Billion by 2030
PR Newswire
DUBLIN, May 20, 2022

DUBLIN, May 20, 2022 /PRNewswire/ — The “Biotechnology & Pharmaceutical Services Outsourc…

Published

on

The Worldwide Biotechnology & Pharmaceutical Services Outsourcing Industry is Expected to Reach $108 Billion by 2030

PR Newswire

DUBLIN, May 20, 2022 /PRNewswire/ -- The "Biotechnology & Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report by Services (Consulting, Auditing And Assessment, Regulatory Affairs), by End Use (Pharma, Biotech), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 108.0 billion by 2030. The market is expected to expand at a CAGR of 5.5% from 2022 to 2030.

The COVID-19 pandemic has significantly impacted Biotechnology and Pharmaceutical third-party service providers as well as clinical trials, resulting in trial delay, suspensions, and terminations. The global crisis has stressed the need for virtual trials and leveraging technology and software solutions. The recovery from the pandemic has led to increasing adoption of machine learning-based platforms, artificial intelligence, automation in drug manufacturing, and innovative trial designs are projected to transform the CRO and CMO landscape in the coming years.

Biopharmaceutical and pharmaceutical investments in novel and innovative therapies, for instance, regenerative medicine, are driving the R&D activity together with drug development services. The high demand for biologics along with small molecules has led to the expansion of service portfolios of Contract Manufacturing Organizations (CMOs)/Contract Research Organizations (CROs) for biotechnology and pharmaceutical production.

Small pharma/ biotech companies are facing challenges while performing in-house development, manufacturing, regulatory affairs, product maintenance, product design and development, product testing and validation, and training and education such as lack of substantial expertise and expensive capability. This in turn has created lucrative opportunities for the growth of CMOs and CROs. Contract services are growing and becoming strategic, targeted, and planned. These factors are expected to play a pivotal role in enhancing the share of CMOs/CROs in the overall market.

Growing pricing pressure, regulatory challenges, and patent expiration have led to shrinking margins in the biotech and pharmaceutical industry. Contract services are considered a "strategic competitive weapon" among the companies, as these services help overcome these issues. These services offer cost saving to their clients as choosing sustainable suppliers could lead to reduced costs in the long run.

They also help save time utilized in the operations and management of a production and research facility. Contract research and manufacturing allows low-cost product development and manufacturing cost of a product. Furthermore, outsourcing services assist in overcoming trade barriers and facilitate the entry of firms into the foreign market. Owing to these advantages, several firms choose to outsource services rather than investing capital in production equipment and hiring skilled labor.

The biologics industry has grown substantially in recent years to include novel product types including nanobodies, rDNA, synthetic vaccines, fusion proteins, soluble receptors, immunoconjugates, and immunotherapeutics. Owing to the revolutionization of disease therapy through biologics, this sector has also provided many opportunities to explore hybrid structures that combine biologics with well-defined chemical entities. The significant growth of biologics is expected to drive the demand for outsourcing of biologics development and manufacturing.

Biotechnology & Pharmaceutical Services Outsourcing Market Report Highlights

  • The consulting segment is expected to dominate the market with a share of 19.5% in 2021. Owing to the increase in the number of fraudulent cases, discrepancies in intellectual property rights, and rise in technological innovations.
  • Based on service, the others segment is expected to witness the highest CAGR of 6.4% over the forecast period owing to increasing focus on generic and biosimilar in developing regions.
  • The pharma segment is expected to witness a CAGR of 5.7% over the forecast period as the pharmaceutical companies outsource internal activities at a larger scale due to rising pricing pressure, and growth of generics in the industry.
  • North America dominated the market and accounted for the largest revenue share of 53.8% in 2021 due to the presence of a large number of biotechnology and pharmaceutical companies and the quality of services offered by the CROs and CMOs in the region.
  • In Asia Pacific, the market is anticipated to register the highest CAGR of 6.1% over the forecast period owing to improved regulatory frameworks, the high scope for cost savings, and the presence of cheap skilled personnel.

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Biotechnology and Pharmaceutical Services Outsourcing Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Driver Analysis
3.2.1 Increasing outsourcing of R&D activities
3.2.2 Changing regulatory landscape
3.2.3 Increasing focus on core competencies by pharmaceutical and biotechnology companies
3.2.4 Growing drug development costs coupled with high clinical development failure rates
3.2.5 Increasing mergers and collaborations
3.3 Market Restraint Analysis
3.3.1 Monitoring issues and lack of standardization
3.3.2 Loss of control
3.3.3 Data security issues
3.4 Penetration & Growth Prospect Mapping
3.5 Porter's Five Forces Analysis
3.6 PESTEL Analysis
3.7 End-use Perception Analysis
3.7.1 Why do you outsource Biotechnology and Pharmaceutical services to CROs?
3.7.2 Percentage of outsourcing of different services.
3.7.3 Importance of CRO selection parameters (Ranking from 1 to 5, where 1-least important and 5-most important).
3.8 Service Price Analysis
3.8.1 Pricing strategy
3.8.1.1 Transactional business models
3.8.1.2 Performance-based business models
3.8.1.3 Outcome-based business models
3.8.2 Consulting rates
3.8.3 Heat map for pricing analysis

Chapter 4 Biotechnology and Pharmaceutical Services Outsourcing Market: Service Segment Analysis
4.1 Biotechnology and Pharmaceutical Services Outsourcing: Market Share Analysis, 2021 & 2030
4.2 Consulting
4.2.1 Consulting Market, 2018-2030 (USD Million)
4.2.2 Regulatory compliance
4.2.2.1 Regulatory compliance market, 2018-2030 (USD Million)
4.2.3 Remediation
4.2.3.1 Remediation market, 2018-2030 (USD Million)
4.2.4 Quality management systems consulting
4.2.4.1 Quality management systems consulting market, 2018-2030 (USD Million)
4.2.5 Others
4.2.5.1 Others market, 2018-2030 (USD Million)
4.3 Auditing and assessment
4.3.1 Auditing and assessment market, 2018-2030 (USD Million)
4.4 Regulatory affairs
4.4.1 Regulatory affairs market, 2018-2030 (USD Million)
4.4.2 Clinical trial applications & product registration
4.4.2.1 Clinical trial applications & product registration market, 2018-2030 (USD Million)
4.4.3 Regulatory writing & publishing
4.4.3.1 Regulatory writing & publishing market, 2018-2030 (USD Million)
4.4.4 Legal representation
4.4.4.1 Legal representation market, 2018-2030 (USD Million)
4.4.5 Others
4.4.5.1 Others market, 2018-2030 (USD Million)
4.5 Product Maintenance
4.5.1 Product maintenance market, 2018-2030 (USD Million)
4.6 Product Design & Development
4.6.1 Product Design & Development market, 2018-2030 (USD Million)
4.7 Product Testing & Validation
4.7.1 Product Testing & Validation market, 2018-2030 (USD Million)
4.8 Training & Education
4.8.1 Training & Education market, 2018-2030 (USD Million)
4.9 Others
4.9.1 Others market, 2018-2030 (USD Million)

Chapter 5 Biotechnology and Pharmaceutical Services Outsourcing Market: End use Segment Analysis
5.1 Biotechnology and Pharmaceutical Services Outsourcing: Market Share Analysis, 2021 & 2030
5.2 Pharmaceutical Companies
5.2.1 Pharmaceutical Companies market, 2018-2030 (USD Million)
5.3 Biotech Companies
5.3.1 Biotech Companies market, 2018-2030 (USD Million)

Chapter 6 Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Analysis
6.1 Biotechnology and Pharmaceutical Services Outsourcing: Market Share Analysis, 2021 & 2030
6.2 North America
6.2.1 North America Market, 2018-2030 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Market, 2018-2030 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Market, 2018-2030 (USD Million)
6.3 Europe
6.3.1 Europe Market, 2018-2030 (USD Million)
6.3.2 U.K.
6.3.2.1 U.K. Market, 2018-2030 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Market, 2018-2030 (USD Million)
6.3.4 France
6.3.4.1 France Market, 2018-2030 (USD Million)
6.3.5 Italy
6.3.5.1 Italy Market, 2018-2030 (USD Million)
6.3.6 Spain
6.3.6.1 Spain Market, 2018-2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Market, 2018-2030 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Market, 2018-2030 (USD Million)
6.4.3 China
6.4.3.1 China Market, 2018-2030 (USD Million)
6.4.4 India
6.4.4.1 India Market, 2018-2030 (USD Million)
6.4.5 Australia
6.4.5.1 Australia Market, 2018-2030 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea Market, 2018-2030 (USD Million)
6.5 Latin America
6.5.1 Latin America market, 2018-2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil market, 2018-2030 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico market, 2018-2030 (USD Million)
6.5.4 Argentina
6.5.4.1 Argentina market, 2018-2030 (USD Million)
6.6 MEA
6.6.1 MEA market, 2018-2030 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa market, 2018-2030 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia market, 2018-2030 (USD Million)
6.6.4 UAE
6.6.4.1 UAE market, 2018-2030 (USD Million)

Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Company Profiles
7.2.1 The Quantic Group
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Service benchmarking
7.2.2 IQVIA HOLDINGS, INC.
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Service benchmarking
7.2.2.4 Strategic Initiatives
7.2.3 Parexel International Corporation
7.2.3.1Company overview
7.2.3.2 Financial performance
7.2.3.3 Service benchmarking
7.2.3.4 Strategic Initiatives
7.2.4 Lachman Consultant Services
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Service benchmarking
7.2.5 GMP Pharmaceuticals
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Service benchmarking
7.2.5.4 Strategic Initiatives
7.2.6 Concept Heidelberg GmbH
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Service benchmarking
7.2.7 Covance, INC.
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Service benchmarking
7.2.8 Charles River
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Service benchmarking
7.2.8.4 Strategic Initiatives
7.2.9 PRA Health Sciences
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Service benchmarking
7.2.9.4 Strategic Initiatives
7.2.10 ICON plc
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Service benchmarking
7.2.10.4 Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/h0pkqh

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



View original content:https://www.prnewswire.com/news-releases/the-worldwide-biotechnology--pharmaceutical-services-outsourcing-industry-is-expected-to-reach-108-billion-by-2030-301551958.html

SOURCE Research and Markets

Read More

Continue Reading

International

Analyst reviews Apple stock price target amid challenges

Here’s what could happen to Apple shares next.

Published

on

They said it was bound to happen.

It was Jan. 11, 2024 when software giant Microsoft  (MSFT)  briefly passed Apple  (AAPL)  as the most valuable company in the world.

Microsoft's stock closed 0.5% higher, giving it a market valuation of $2.859 trillion. 

It rose as much as 2% during the session and the company was briefly worth $2.903 trillion. Apple closed 0.3% lower, giving the company a market capitalization of $2.886 trillion. 

"It was inevitable that Microsoft would overtake Apple since Microsoft is growing faster and has more to benefit from the generative AI revolution," D.A. Davidson analyst Gil Luria said at the time, according to Reuters.

The two tech titans have jostled for top spot over the years and Microsoft was ahead at last check, with a market cap of $3.085 trillion, compared with Apple's value of $2.684 trillion.

Analysts noted that Apple had been dealing with weakening demand, including for the iPhone, the company’s main source of revenue. 

Demand in China, a major market, has slumped as the country's economy makes a slow recovery from the pandemic and competition from Huawei.

Sales in China of Apple's iPhone fell by 24% in the first six weeks of 2024 compared with a year earlier, according to research firm Counterpoint, as the company contended with stiff competition from a resurgent Huawei "while getting squeezed in the middle on aggressive pricing from the likes of OPPO, vivo and Xiaomi," said senior Analyst Mengmeng Zhang.

“Although the iPhone 15 is a great device, it has no significant upgrades from the previous version, so consumers feel fine holding on to the older-generation iPhones for now," he said.

A man scrolling through Netflix on an Apple iPad Pro. Photo by Phil Barker/Future Publishing via Getty Images.

Future Publishing/Getty Images

Big plans for China

Counterpoint said that the first six weeks of 2023 saw abnormally high numbers with significant unit sales being deferred from December 2022 due to production issues.

Apple is planning to open its eighth store in Shanghai – and its 47th across China – on March 21.

Related: Tech News Now: OpenAI says Musk contract 'never existed', Xiaomi's EV, and more

The company also plans to expand its research centre in Shanghai to support all of its product lines and open a new lab in southern tech hub Shenzhen later this year, according to the South China Morning Post.

Meanwhile, over in Europe, Apple announced changes to comply with the European Union's Digital Markets Act (DMA), which went into effect last week, Reuters reported on March 12.

Beginning this spring, software developers operating in Europe will be able to distribute apps to EU customers directly from their own websites instead of through the App Store.

"To reflect the DMA’s changes, users in the EU can install apps from alternative app marketplaces in iOS 17.4 and later," Apple said on its website, referring to the software platform that runs iPhones and iPads. 

"Users will be able to download an alternative marketplace app from the marketplace developer’s website," the company said.

Apple has also said it will appeal a $2 billion EU antitrust fine for thwarting competition from Spotify  (SPOT)  and other music streaming rivals via restrictions on the App Store.

The company's shares have suffered amid all this upheaval, but some analysts still see good things in Apple's future.

Bank of America Securities confirmed its positive stance on Apple, maintaining a buy rating with a steady price target of $225, according to Investing.com

The firm's analysis highlighted Apple's pricing strategy evolution since the introduction of the first iPhone in 2007, with initial prices set at $499 for the 4GB model and $599 for the 8GB model.

BofA said that Apple has consistently launched new iPhone models, including the Pro/Pro Max versions, to target the premium market. 

Analyst says Apple selloff 'overdone'

Concurrently, prices for previous models are typically reduced by about $100 with each new release. 

This strategy, coupled with installment plans from Apple and carriers, has contributed to the iPhone's installed base reaching a record 1.2 billion in 2023, the firm said.

More Tech Stocks:

Apple has effectively shifted its sales mix toward higher-value units despite experiencing slower unit sales, BofA said.

This trend is expected to persist and could help mitigate potential unit sales weaknesses, particularly in China. 

BofA also noted Apple's dominance in the high-end market, maintaining a market share of over 90% in the $1,000 and above price band for the past three years.

The firm also cited the anticipation of a multi-year iPhone cycle propelled by next-generation AI technology, robust services growth, and the potential for margin expansion.

On Monday, Evercore ISI analysts said they believed that the sell-off in the iPhone maker’s shares may be “overdone.”

The firm said that investors' growing preference for AI-focused stocks like Nvidia  (NVDA)  has led to a reallocation of funds away from Apple. 

In addition, Evercore said concerns over weakening demand in China, where Apple may be losing market share in the smartphone segment, have affected investor sentiment.

And then ongoing regulatory issues continue to have an impact on investor confidence in the world's second-biggest company.

“We think the sell-off is rather overdone, while we suspect there is strong valuation support at current levels to down 10%, there are three distinct drivers that could unlock upside on the stock from here – a) Cap allocation, b) AI inferencing, and c) Risk-off/defensive shift," the firm said in a research note.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

International

Major typhoid fever surveillance study in sub-Saharan Africa indicates need for the introduction of typhoid conjugate vaccines in endemic countries

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high…

Published

on

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

Credit: IVI

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

 

The findings from this 4-year study, the Severe Typhoid in Africa (SETA) program, offers new typhoid fever burden estimates from six countries: Burkina Faso, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria, with four countries recording more than 100 cases for every 100,000 person-years of observation, which is considered a high burden. The highest incidence of typhoid was found in DRC with 315 cases per 100,000 people while children between 2-14 years of age were shown to be at highest risk across all 25 study sites.

 

There are an estimated 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths. However, with generic symptoms such as fever, fatigue, and abdominal pain, and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries.

 

“Our goal through SETA was to address these gaps in typhoid disease burden data,” said lead author Dr. Florian Marks, Deputy Director General of the International Vaccine Institute (IVI). “Our estimates indicate that introduction of TCV in endemic settings would go to lengths in protecting communities, especially school-aged children, against this potentially deadly—but preventable—disease.”

 

In addition to disease incidence, this study also showed that the emergence of antimicrobial resistance (AMR) in Salmonella Typhi, the bacteria that causes typhoid fever, has led to more reliance beyond the traditional first line of antibiotic treatment. If left untreated, severe cases of the disease can lead to intestinal perforation and even death. This suggests that prevention through vaccination may play a critical role in not only protecting against typhoid fever but reducing the spread of drug-resistant strains of the bacteria.

 

There are two TCVs prequalified by the World Health Organization (WHO) and available through Gavi, the Vaccine Alliance. In February 2024, IVI and SK bioscience announced that a third TCV, SKYTyphoid™, also achieved WHO PQ, paving the way for public procurement and increasing the global supply.

 

Alongside the SETA disease burden study, IVI has been working with colleagues in three African countries to show the real-world impact of TCV vaccination. These studies include a cluster-randomized trial in Agogo, Ghana and two effectiveness studies following mass vaccination in Kisantu, DRC and Imerintsiatosika, Madagascar.

 

Dr. Birkneh Tilahun Tadesse, Associate Director General at IVI and Head of the Real-World Evidence Department, explains, “Through these vaccine effectiveness studies, we aim to show the full public health value of TCV in settings that are directly impacted by a high burden of typhoid fever.” He adds, “Our final objective of course is to eliminate typhoid or to at least reduce the burden to low incidence levels, and that’s what we are attempting in Fiji with an island-wide vaccination campaign.”

 

As more countries in typhoid endemic countries, namely in sub-Saharan Africa and South Asia, consider TCV in national immunization programs, these data will help inform evidence-based policy decisions around typhoid prevention and control.

 

###

 

About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO) and developed a new-generation typhoid conjugate vaccine that is recently pre-qualified by WHO.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, a Country Office in Austria, and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

CONTACT

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int


Read More

Continue Reading

International

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

Earlier today, CNBC’s…

Published

on

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever... And Debt Explodes

Earlier today, CNBC's Brian Sullivan took a horse dose of Red Pills when, about six months after our readers, he learned that the US is issuing $1 trillion in debt every 100 days, which prompted him to rage tweet, (or rageX, not sure what the proper term is here) the following:

We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.   

Maybe it will never matter.   Maybe MMT is real.   Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.

I have no idea.  Only time will tell.   But it’s going to be fascinating to watch it play out.

He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."

According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.

The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...

... and spending which is about 50% higher compared to where it was in 2020.

The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.

And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.

But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).

And it gets even worse, because we are now in the ponzi finance stage of the Minsky cycle, with total interest on the debt annualizing well above $1 trillion, and rising every day

... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.

We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...

.. which lays out the proposed Biden budget as follows:

The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.

Without them the deficit will grow $19 trillion.

That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.

No family budget or business could exist with this kind of math.

Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.

Tyler Durden Tue, 03/12/2024 - 18:40

Read More

Continue Reading

Trending